Abbott announced late-breaking data for its next-generation Navitor transcatheter aortic valve implantation system. Results from the study supported Navitor’s recent U.S. FDA approval to treat people with severe, symptomatic aortic stenosis who are at high or greater risk for open-heart surgery. The company also showcased late-breaking data for the Amplatzer Amulet Left Atrial Appendage Occluder that continue to highlight the benefits of this device’s immediate and complete closure of the LAA, a differentiator from competing therapies, for patients with atrial fibrillation at risk of stroke.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABT:
- Baird points to elements of Apple report making it ‘less worried’ about DexCom
- Diabetes management stocks slide on report of tech giant’s breakthroughs
- Abbott (NYSE:ABT) at High Legal Risk, According to SEC Report
- Abbott says 399 lawsuits pending in which company is a party
- Abbott says it received civil investigative demand from FTC
